{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:07:05Z","timestamp":1792465625496,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recombinant zoster vaccine [RZV] reduces the short-term risk of herpes zoster [HZ] in patients with inflammatory bowel disease [IBD]. However, there is lack of data regarding the long-term effectiveness in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study was conducted in adults\u2005\u226550 years old using TriNetX database between patients with IBD who received two doses of RZV [IBD-RZV cohort] and patients who did not receive RZV [IBD control cohort]. The primary outcome was risk of incident HZ. One-to-one propensity score matching was performed for demographic parameters, comorbid conditions, and IBD medications. Risk was expressed as adjusted odds ratio [aOR] with 95% confidence intervals [CI].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The IBD-RZV cohort [n\u2005=\u20055489; mean age 63.2\u2005\u00b1\u20059.1 years; 57.2% females] was identified with a mean follow-up of 900.9 days. IBD-RZV cohort had a lower risk of HZ [aOR 0.44, 95% CI 0.32-0.62] compared with IBD control cohort. The risk of HZ was lower in patients aged 50\u201365 years [aOR 0.41, 95% CI 0.25-0.68] and patients\u2005&amp;gt;65 years [aOR 0.64, 95% CI 0.42-0.96]. There was a lower risk of HZ in patients with ulcerative colitis [aOR 0.41, 95% CI 0.27-0.63] and Crohn\u2019s disease [aOR 0.44, 95% CI 0.26-0.74] in the IBD-RZV cohort compared with IBD control cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>RZV is associated with a lower long-term risk of HZ in patients\u2005\u226550 years old with IBD. Given the widespread availability and safety of RZV, more effective vaccination strategies are needed to improve RZV use in this high-risk population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae008","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T18:08:06Z","timestamp":1705342086000},"page":"828-835","source":"Crossref","is-referenced-by-count":23,"title":["Recombinant Zoster Vaccine [RZV] is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-7712","authenticated-orcid":false,"given":"Aakash","family":"Desai","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G","family":"Hashash","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursimran S","family":"Kochhar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Allegheny Health Network , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S","family":"Hayney","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wisconsin-Madison , Madison, WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1960-6611","authenticated-orcid":false,"given":"Freddy","family":"Caldera","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Wisconsin-Madison School of Medicine and Public Health , Madison, WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A","family":"Farraye","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"2024060402063385600_CIT0001","first-page":"2066","article-title":"Inflammatory bowel disease","volume-title":"N Engl J Med","author":"Abraham","year":"2009"},{"key":"2024060402063385600_CIT0002","first-page":"205","article-title":"Epidemiology and risk factors for IBD","volume-title":"Nat Rev Gastroenterol Hepatol","author":"Ananthakrishnan","year":"2015"},{"key":"2024060402063385600_CIT0003","first-page":"337","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume-title":"Gastroenterology","author":"Kirchgesner","year":"2018"},{"key":"2024060402063385600_CIT0004","first-page":"828","article-title":"Relevant infections in inflammatory bowel disease, and their relationship with immunosuppressive therapy and their effects on disease mortality","volume-title":"J Crohns Colitis","author":"Zabana","year":"2019"},{"key":"2024060402063385600_CIT0005","first-page":"192","article-title":"Herpes zoster: a review of clinical manifestations and management","volume-title":"Viruses","author":"Patil","year":"2022"},{"key":"2024060402063385600_CIT0006","first-page":"15016","article-title":"Varicella zoster virus infection","volume-title":"Nat Rev Dis Primers","author":"Gershon","year":"2015"},{"key":"2024060402063385600_CIT0007","first-page":"goad01","article-title":"Incidence and risk of herpes zoster in patients with ulcerative colitis and Crohn\u2019s disease in the USA","volume-title":"Gastroenterol Rep","author":"Singer","year":"2022"},{"key":"2024060402063385600_CIT0008","first-page":"e26863","article-title":"The incidence rate of herpes zoster in inflammatory bowel disease: a meta-analysis of cohort studies","volume-title":"Medicine [Baltimore]","author":"Lai","year":"2021"},{"key":"2024060402063385600_CIT0009","first-page":"1483","article-title":"Incidence and risk factors for Herpes Zoster among patients with inflammatory bowel disease","volume-title":"Clin Gastroenterol Hepatol","author":"Gupta","year":"2006"},{"key":"2024060402063385600_CIT0010","first-page":"85","article-title":"Long-term risk of Herpes Zoster infection in patients with ulcerative colitis receiving tofacitinib","volume-title":"Inflamm Bowel Dis","author":"Winthrop","year":"2022"},{"key":"2024060402063385600_CIT0011","first-page":"666","article-title":"Systematic review with network meta-analysis: risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume-title":"Aliment Pharmacol Ther","author":"Din","year":"2022"},{"key":"2024060402063385600_CIT0012","author":"GSK","year":"2021"},{"key":"2024060402063385600_CIT0013","first-page":"241","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease","volume-title":"Am J Gastroenterol","author":"Farraye","year":"2017"},{"key":"2024060402063385600_CIT0014","author":"CDC","year":"2022"},{"key":"2024060402063385600_CIT0015","first-page":"316","article-title":"Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know","volume-title":"J Crohns Colitis","author":"Schreiner","year":"2020"},{"key":"2024060402063385600_CIT0016","first-page":"4199","article-title":"Effectiveness of recombinant zoster vaccine [RZV] in patients with inflammatory bowel disease","volume-title":"Vaccine","author":"Kochhar","year":"2021"},{"key":"2024060402063385600_CIT0017","first-page":"357","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center\u2019s experience with 400 patients","volume-title":"ACR Open Rheumatol","author":"Stevens","year":"2020"},{"key":"2024060402063385600_CIT0018","first-page":"481","article-title":"Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide","volume-title":"Clin Gastroenterol Hepatol","author":"Guillo","year":"2022"},{"key":"2024060402063385600_CIT0019","first-page":"izac131","article-title":"A systematic review of Crohn\u2019s disease case definitions in administrative or claims databases","volume-title":"Inflamm Bowel Dis","author":"Hutfless","year":"2022"},{"key":"2024060402063385600_CIT0020","first-page":"191","article-title":"Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis","volume-title":"Aliment Pharmacol Ther","author":"Hadi","year":"2021"},{"key":"2024060402063385600_CIT0021","first-page":"1575","article-title":"Risk of severe COVID-19 in patients with inflammatory bowel disease in United States a multicenter research network study","volume-title":"Gastroenterology","author":"Singh","year":"2020"},{"key":"2024060402063385600_CIT0022","first-page":"e17430","article-title":"The risk of herpes zoster virus infection in patients with depression","volume-title":"Medicine [Baltimore]","author":"Choi","year":"2019"},{"key":"2024060402063385600_CIT0023","first-page":"1570","article-title":"Efficacy of recombinant zoster vaccine in patients with inflammatory bowel disease","volume-title":"Clin Gastroenterol Hepatol","author":"Khan","year":"2021"},{"key":"2024060402063385600_CIT0024","first-page":"1226","article-title":"Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials","volume-title":"Rheumatology","author":"Dagnew","year":"2020"},{"key":"2024060402063385600_CIT0025","first-page":"345","article-title":"Frequency of herpes zoster vaccination among inflammatory bowel disease patients","volume-title":"Inflamm Bowel Dis","author":"Khan","year":"2019"},{"key":"2024060402063385600_CIT0026","author":"Ewumi","year":"2023"},{"key":"2024060402063385600_CIT0027","author":"Sagonowsky","year":"2020"},{"key":"2024060402063385600_CIT0028","first-page":"205","article-title":"Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data","volume-title":"Am J Epidemiol","author":"Nelson","year":"2022"},{"key":"2024060402063385600_CIT0029","first-page":"2986","article-title":"Safety of recombinant zoster vaccine in patients with inflammatory bowel disease","volume-title":"Dig Dis Sci","author":"Satyam","year":"2020"},{"key":"2024060402063385600_CIT0030","first-page":"1505","article-title":"Safety of recombinant zoster vaccine in patients with inflammatory bowel disease","volume-title":"J Crohns Colitis","author":"Khan","year":"2022"},{"key":"2024060402063385600_CIT0031","first-page":"1356","article-title":"Vaccination in patients with inflammatory bowel disease","volume-title":"Am J Gastroenterol","author":"Caldera","year":"2020"},{"key":"2024060402063385600_CIT0032","author":"GSK","year":"2021"},{"key":"2024060402063385600_CIT0033","first-page":"1146","article-title":"Herpes zoster and postherpetic neuralgia surveillance using structured electronic data","volume-title":"Mayo Clin Proc","author":"Klompas","year":"2011"},{"key":"2024060402063385600_CIT0034","first-page":"245","article-title":"Incidence of herpes zoster, 1997\u20132002","volume-title":"Epidemiol Infect","author":"Mullooly","year":"2005"},{"key":"2024060402063385600_CIT0035","first-page":"2002","article-title":"Incidence of herpes zoster, before and after varicella-vaccination\u2013associated decreases in the incidence of varicella, 1992\u20132002","volume-title":"J Infect Dis","author":"Jumaan A","year":"2005"},{"key":"2024060402063385600_CIT0036","first-page":"1605","article-title":"The incidence of herpes zoster","volume-title":"Arch Intern Med","author":"Donahue","year":"1995"},{"key":"2024060402063385600_CIT0037","author":"Shingrix.","year":"2018"},{"key":"2024060402063385600_CIT0038","first-page":"1326","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease","volume-title":"Aliment Pharmacol Ther","author":"Caldera","year":"2023"},{"key":"2024060402063385600_CIT0039","first-page":"1681","article-title":"Impact of holding immunosuppressive therapy in patients with inflammatory bowel disease around mRNA COVID-19 vaccine administration on humoral immune response and development of COVID-19 infection","volume-title":"J Crohns Colitis","author":"Motwani","year":"2023"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae008\/56432105\/jjae008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/6\/828\/58069626\/jjae008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/6\/828\/58069626\/jjae008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T02:07:07Z","timestamp":1717466827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/6\/828\/7550023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae008","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,1,15]]}}}